Litcius/Paper detail

Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T <sub>H</sub> 1-T <sub>H</sub> 17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei

Daniel Tapia, Javier I. Sanchez-Villamil, Heather L. Stevenson, Alfredo G. Torres

2021mBio28 citationsDOIOpen Access PDF

Abstract

Melioidosis is a complex human disease associated with a wide range of complications caused by the Gram-negative bacillus Burkholderia pseudomallei. The global burden of melioidosis is estimated to have 165,000 cases per year and 89,000 fatal outcomes. The endemicity of B. pseudomallei includes a wide range of tropical regions in Asia, Africa, Latin America, and Australia. Therefore, a viable alternative to prevent human infections is the development of an effective vaccine; however, no approved vaccine for human use is available. This study provides a vaccine strategy against B. pseudomallei and an immune-stimulatory platform to induce strong humoral and T-cell-mediated immunity.

Topics & Concepts

AntigenHumoral immunityAdjuvantMicrobiologyImmunogenicityBurkholderia pseudomalleiImmunizationImmunologyMelioidosisImmunityBiologyCellular immunityVaccinationImmune systemVirologyBacteriaGeneticsBurkholderia infections and melioidosisBrucella: diagnosis, epidemiology, treatment
Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T <sub>H</sub> 1-T <sub>H</sub> 17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei | Litcius